Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$0.17.

  • Cardiff Oncology's EPS (Basic) rose 3200.0% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.79, marking a year-over-year increase of 1595.74%. This contributed to the annual value of -$0.95 for FY2024, which is 257.36% down from last year.
  • Latest data reveals that Cardiff Oncology reported EPS (Basic) of -$0.17 as of Q3 2025, which was up 3200.0% from -$0.21 recorded in Q2 2025.
  • Cardiff Oncology's 5-year EPS (Basic) high stood at -$0.14 for Q1 2021, and its period low was -$0.26 during Q2 2024.
  • Its 5-year average for EPS (Basic) is -$0.22, with a median of -$0.22 in 2023.
  • Over the last 5 years, Cardiff Oncology's EPS (Basic) had its largest YoY gain of 6666.67% in 2021, and its largest YoY loss of 20000.0% in 2021.
  • Cardiff Oncology's EPS (Basic) (Quarter) stood at -$0.24 in 2021, then increased by 16.67% to -$0.2 in 2022, then fell by 5.0% to -$0.21 in 2023, then dropped by 17.85% to -$0.25 in 2024, then skyrocketed by 31.31% to -$0.17 in 2025.
  • Its EPS (Basic) stands at -$0.17 for Q3 2025, versus -$0.21 for Q2 2025 and -$0.2 for Q1 2025.